Minerva Biotechnologies is developing cancer immunotherapies and cancer drugs to target 80% of solid tumors and to prevent cancer metastasis. Our stem cell technology could transform the field of regenerative medicine.
We discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. We can reverse the reprogramming and make cancer cells mature so that cancer growth is turned off. This is a unique approach to curing cancer.
Our patents cover:
- The molecules that regulate both cancer cell growth and stem cell growth.
- Novel growth factor receptor (target) – MUC1* (pronounced MUK1 star). Minerva’s patents cover the entirety of the MUC1* extra-cellular domain, all antibodies that bind to it and block its tumorigenic activity;
- The growth factors that activate MUC1* – NM23 & a metastatic growth factor.
- How to turn the molecules on or off. OFF – to stop cancer cell growth. ON – to make stem cells grow
Together this IP gives Minerva the most significant broad based system for detecting, halting and destroying most solid tumor cancers.
Our commercialization pipeline includes:
- CAR T-Cell Anti-MUC1* Single chain fragment variable (scFv) from our anti-MUC1* antibody as the targeting head for a CAR T immuno-oncology therapeutic. Minerva has developed its proprietary CAR constructs with clean IP. The success of other CAR T companies has been limited to blood cancers.
- Anti-MUC1* antibody will target over 80% of cancers (Herceptin with annual sales of $7b a year targets 3% of cancers). Could be most valuable oncology drug in the world. Has been shown to reverse acquired drug resistance to chemotherapy drugs in vitro.
- Anti-metastasis antibody to turn off the metastatic growth factor that we have found in all metastatic cancers we have looked at. This could be applicable for all cancers.
- Stem cell technology to facilitate regenerative therapies targeting diseases of the heart, central nervous system, liver, diabetes and macular degeneration. Our stem cell reagents can also facilitate the next generation of stem cell research.